Drug intelligence / Profile preview

WD-930

Development stage: Preclinical
Lead developer: Zhejiang Wenda Pharmaceutical Technology
Modality: Small Molecules

Overview

WD-930 is a small molecule drug candidate currently in preclinical development by Ningbo Wenda Pharmaceutical Technology for the treatment of advanced cancer. As of the current reporting, the specific biological target and mechanism of action for WD-930 have not been publicly disclosed by the developer. It is part of a broader oncology and immunology pipeline that includes other small molecules targeting BET and TYK2 proteins, though WD-930 remains in the early discovery and preclinical stages.

Beyond the preview

Go deeper on WD-930.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD-930.

Explore the full profile